ACADIA Pharmaceuticals Inc.  

(Public, NASDAQ:ACAD)   Watch this stock  
Find more results for ACAD
38.14
-0.09 (-0.24%)
Mar 3 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 37.94 - 38.54
52 week 15.64 - 38.54
Open 38.22
Vol / Avg. 0.00/1.30M
Mkt cap 3.83B
P/E     -
Div/yield     -
EPS -0.94
Shares 100.05M
Beta 2.98
Inst. own 96%
Jun 1, 2015
ACADIA Pharmaceuticals Annual Shareholder Meeting (Estimated) Add to calendar
May 4, 2015
Q1 2015 ACADIA Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 10, 2015
ACADIA Pharmaceuticals Inc at ROTH Conference - 1:00PM EDT - Add to calendar
Mar 3, 2015
ACADIA Pharmaceuticals Inc at Cowen Health Care Conference
Feb 26, 2015
Q4 2014 ACADIA Pharmaceuticals Inc Earnings Call - Webcast
Feb 26, 2015
Q4 2014 ACADIA Pharmaceuticals Inc Earnings Release
Jan 13, 2015
ACADIA Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 13, 2015
ACADIA Pharmaceuticals Inc at JPMorgan Healthcare Conference
Dec 10, 2014
ACADIA Pharmaceuticals Inc at Oppenheimer Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -59095.83% -77062.50%
Operating margin -59487.50% -77691.66%
EBITD margin - -77520.00%
Return on average assets -34.10% -35.94%
Return on average equity -35.56% -37.62%
Employees 48 -
CDP Score - -

Address

SUITE 100, 11085 TORREYANA ROAD
SAN DIEGO, CA 92121
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ACADIA Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in neurological and related central nervous system disorders. It has a pipeline of product candidates led by NUPLAZID (pimavanserin), which is in Phase III development as a treatment for Parkinson's disease psychosis.

Officers and directors

Leslie L. Iversen Ph.D. Independent Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
Uli Hacksell Ph.D. President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Stephen R. Davis Executive Vice President, Chief Financial Officer and Chief Business Officer
Age: 53
Bio & Compensation  - Reuters
Roger G. Mills M.D. Executive Vice President - Development, Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Terrence O. Moore Executive Vice President, Chief Commercial Officer
Age: 59
Bio & Compensation  - Reuters
Glenn F. Baity Vice President, General Counsel, Secretary
Age: 44
Bio & Compensation  - Reuters
Stephen R. Biggar M.D., Ph.D. Independent Director
Age: 43
Bio & Compensation  - Reuters
Michael T. Borer Independent Director
Age: 55
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 56
Bio & Compensation  - Reuters
Mary A. Gray Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters